Consultant to big pharma joins Avacta
Avacta Group (AIM: AVCT), a UK life sciences company developing innovative, targeted oncology drugs and diagnostics, has appointed Simon Bennett as chief business officer of the therapeutics division.
Dr Bennett has more than 26 years' commercial experience in the biopharma industry, and has worked with companies from large and mid-sized pharma such as Bristol Myers Squibb (NYSE: BMY) and Menarini Group to early stage biotechs, supporting business development and licensing activities.
"Avacta is at a pivotal point, having recently announced clinical data that have already begun to generate interest from potential commercial partners"Indeed, he has been involved in all aspects of business and corporate development including having involvement in more than 80 commercial deals across Europe, North America, Australasia, Japan, Russia and South America.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze